ALLR

Allarity Therapeutics Inc

0.8754

Nov 02 • 9:30 AM ET +0.0050 (0.57%)

Healthcare Biotechnology USA Nano NASD

Oct 30, 8:20 AMAllarity Therapeutics secures first revenue-generating CLIA laboratory services contract with a European biotech

Peers: ACRV APRE ZNTL LTRN VSTM CRDF TPST ACTU MBRX PRLD

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	13.93M
Enterprise Value	9.24M
Income	-12.33M
Sales	0.34M
Book/sh	0.22
Cash/sh	1.70
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Dec 21, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	40.97
P/B	3.94
P/C	0.52
P/FCF	-
EV/EBITDA	-
EV/Sales	27.18
Quick Ratio	1.11
Current Ratio	1.11
Debt/Eq	6.30
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.79
EPS next Y	-0.86
EPS next Q	-0.21
EPS this Y	-2.56%
EPS next Y	-7.50%
EPS next 5Y	-
EPS past 3/5Y	99.25% 94.60%
Sales past 3/5Y	- -
EPS Y/Y TTM	91.38%
Sales Y/Y TTM	-
EPS Q/Q	-43.34%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	16.00% -

Insider Own	5.35%
Insider Trans	0.00%
Inst Own	8.05%
Inst Trans	2.30%
ROA	-46.26%
ROE	-157.09%
ROIC	-348.81%
Gross Margin	100.00%
Oper. Margin	-3128.99%
Profit Margin	-3575.07%
SMA20	-2.91%
SMA50	-19.34%
SMA200	-28.04%
Trades

Shs Outstand	15.91M
Shs Float	15.06M
Short Float	1.12%
Short Ratio	1.51
Short Interest	0.17M
52W High	1.84 -52.41%
52W Low	0.77 13.88%
Volatility	7.68% 7.66%
ATR (14)	0.07
RSI (14)	39.77
Beta	0.57
Rel Volume	1.27
Avg Volume	111.10K
Volume	7,048

Perf Week	-4.34%
Perf Month	-15.83%
Perf Quarter	-33.18%
Perf Half Y	-29.97%
Perf YTD	-18.94%
Perf Year	-39.63%
Perf 3Y	-99.73%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	11.00
Prev Close	0.87
Price	0.88
Change %	0.57%

Consensus

Strong Buy

Avg. Price Target

$11.00

Implied Upside

+1,156.6%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 28, 2025	Initiated	AAscendiant Capital Markets	Buy	$9	+928.1%

Oct-30-26 07:45AM	Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue (GlobeNewswire)
Sep-30-26 09:00AM	Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor to Drive Stenoparib's Clinical Development (GlobeNewswire) +8.80%
Sep-28-26 08:00AM	Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research (GlobeNewswire) -5.98%
Sep-15-26 08:00AM	Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP Companion Diagnostic, Further Strengthening Stenoparib Development (GlobeNewswire) -5.13%
Sep-11-26 08:00AM	Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement (GlobeNewswire)
08:00AM	Loading…
Aug-14-26 08:00AM	Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign (GlobeNewswire)
Jul-07-26 08:00AM	Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP Testing for FDA Registration (GlobeNewswire) -5.83%
Jun-30-26 08:00AM	Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP Companion Diagnostic (GlobeNewswire)
Jun-18-26 08:00AM	Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 (GlobeNewswire) +6.72%
May-15-26 04:30PM	Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers (GlobeNewswire) -10.60% +5.93%
May-08-26 08:45AM	Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm (GlobeNewswire)
May-05-26 08:00AM	Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign (GlobeNewswire) +12.00%
Apr-27-26 08:00AM	Allarity Therapeutics Announces that the Stenoparib DRP Test Has Received a Notice of Allowance from the US Patent and Trademark Office (GlobeNewswire)
Apr-21-26 08:00AM	Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer (GlobeNewswire) +10.40%
Mar-31-26 08:00AM	Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress (GlobeNewswire)
08:19AM	Loading…
Mar-07-26 08:19AM	Allarity closes $20M financing for stenoparib advancement (TipRanks)
Mar-06-26 08:00AM	Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization (GlobeNewswire) +21.57%
Feb-18-26 08:15AM	Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need (GlobeNewswire) +8.67%
Feb-03-26 08:00AM	Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment (GlobeNewswire) -8.06%
Jan-01-26 08:05AM	Allarity CEO says 2026 represents an inflection point (TipRanks)
Dec-31-25 08:00AM	Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders (GlobeNewswire) +6.93%
Nov-14-25 09:00AM	Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-22-25 08:00AM	Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months (GlobeNewswire) +15.58%
Sep-17-25 08:00AM	Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 (GlobeNewswire)
Aug-29-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +51.92%
08:00AM	Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer (GlobeNewswire)
Aug-15-25 04:30PM	Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships (GlobeNewswire) -5.00%
Jul-15-25 08:00AM	Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform Utilization (GlobeNewswire)
Jul-07-25 08:00AM	Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer (GlobeNewswire)
08:00AM	Loading…
Jun-30-25 08:00AM	Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic (GlobeNewswire)
Jun-27-25 08:00AM	Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer (GlobeNewswire)
Jun-11-25 04:05PM	Allarity Therapeutics Announces Changes to Board of Directors (GlobeNewswire) -5.31%
Jun-04-25 08:00AM	Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action (GlobeNewswire)
Jun-02-25 08:00AM	Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer (GlobeNewswire)
May-12-25 08:00AM	Allarity Therapeutics Announces Participation in Pharma Partnering Summit US (GlobeNewswire)
May-09-25 04:05PM	Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment (GlobeNewswire)
Apr-25-25 08:00AM	Allarity Therapeutics Presents Novel Drug Response Predictor DRP for Daratumumab in Multiple Myeloma at AACR 2025 (GlobeNewswire) +5.61%
Mar-31-25 04:05PM	Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) -9.91%
Mar-24-25 08:00AM	Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares (GlobeNewswire)
Mar-17-25 08:00AM	Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology (GlobeNewswire)
Mar-13-25 08:30AM	Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission (GlobeNewswire) -11.48%
Mar-06-25 08:00AM	Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration (GlobeNewswire)
Mar-03-25 08:00AM	Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program (GlobeNewswire) +10.19%
Feb-26-25 08:00AM	Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit (GlobeNewswire) +10.17%
Feb-24-25 08:00AM	Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients (GlobeNewswire) -13.99%
Feb-06-25 08:00AM	Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer (GlobeNewswire)
Jan-30-25 08:00AM	Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC (GlobeNewswire) -16.31%
Nov-18-24 08:00AM	Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements (GlobeNewswire) -8.33%
Nov-14-24 08:00AM	Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights (GlobeNewswire)
Oct-22-24 08:00AM	Allarity Therapeutics to be Granted European Patent for DRP Companion Diagnostic for Stenoparib (GlobeNewswire)
Oct-10-24 08:00AM	Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement (GlobeNewswire)
Oct-03-24 08:00AM	Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program (GlobeNewswire)
Sep-16-24 08:00AM	Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial (GlobeNewswire)
Sep-13-24 08:45AM	Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.40%
Sep-11-24 08:00AM	Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) (GlobeNewswire) +11.02%
Aug-23-24 08:15AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws (PR Newswire)
Aug-14-24 03:58PM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws (PR Newswire) +5.56%
Aug-08-24 08:05PM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws (PR Newswire)
Aug-02-24 09:18AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws (PR Newswire) -8.56%
Jul-31-24 10:30AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws (PR Newswire)
Jul-26-24 09:00AM	Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting (GlobeNewswire) +14.90%
Jul-24-24 06:00AM	Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares (GlobeNewswire) +7.33%
Jul-22-24 06:30AM	Allarity Therapeutics Outlines Company's 2024 Progress and Objectives (GlobeNewswire)
Jun-27-24 08:00AM	Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance (GlobeNewswire)
Jun-25-24 08:00AM	Allarity Therapeutics' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer (GlobeNewswire) -34.80%
Jun-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -28.40%
May-20-24 08:00AM	Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement (GlobeNewswire)
May-15-24 06:53AM	ALLR Stock Earnings: Allarity Therapeutics Reported Results for Q1 2024 (InvestorPlace) -13.75%
May-14-24 04:01PM	Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances (GlobeNewswire)
May-07-24 12:00PM	All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy (Zacks) -18.68%
09:30AM	Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock (GlobeNewswire)
May-06-24 10:21AM	Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule (MT Newswires) -9.90%
08:00AM	Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 (GlobeNewswire)
May-02-24 11:27AM	JPMorgan Just Raised Its Price Target on Carvana (CVNA) Stock (InvestorPlace) -10.22%
11:13AM	Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job Cuts (InvestorPlace)
08:00AM	Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer (GlobeNewswire)
Apr-29-24 07:00AM	Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement (GlobeNewswire) -5.48%
Apr-17-24 09:10AM	Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) (GlobeNewswire) -10.71%
Apr-12-24 08:18AM	Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today? (InvestorPlace) -8.58%
Apr-04-24 09:15AM	Allarity Therapeutics Announces 1-for-20 Reverse Stock Split (GlobeNewswire) +5.78%
Mar-27-24 08:30AM	Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer (GlobeNewswire)
Mar-25-24 07:30AM	Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) (GlobeNewswire) -12.25%
Mar-08-24 07:15AM	Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-28-24 06:00AM	Allarity Therapeutics to Present at Biomarkers 2024 (GlobeNewswire) +8.06%
Dec-12-23 06:00AM	Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor (GlobeNewswire)
Dec-05-23 10:07AM	Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today? (InvestorPlace)
07:30AM	Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic (GlobeNewswire)
Oct-02-23 07:00AM	Allarity Therapeutics to Present at Biomarkers Europe 2023 (GlobeNewswire)
Sep-14-23 09:25AM	Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology (ACCESSWIRE)
Aug-30-23 04:05PM	PLOS ONE Publishes Data on Allarity Therapeutics DRP® Companion Diagnostic for Dovitinib (GlobeNewswire) +16.35%
Jul-31-23 06:00AM	Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol with DRP® Companion Diagnostics (GlobeNewswire)
Jul-24-23 06:00AM	Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives (GlobeNewswire)
Jul-12-23 04:00AM	ALLR: IXEMPRA Clinical Update (Zacks)
Jul-06-23 06:00AM	Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering (GlobeNewswire) -53.99%
Jul-05-23 09:45AM	Initial Data from Allaritys Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients (GlobeNewswire) +31.43%
Jun-28-23 11:55AM	Allarity Therapeutics Announces Reverse Stock Split of Common Stock (GlobeNewswire) +16.01%
Jun-27-23 06:16PM	Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split (GlobeNewswire)
Jun-20-23 04:05PM	Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders (GlobeNewswire) -6.29%
May-30-23 06:00AM	First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire) -16.13%

Show Previous News

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The company is focused on development of stenoparib, a novel PARP and tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity Therapeutics was founded by Steen Knudsen and Thomas H. Jensen in 2004 and is headquartered in Tarpon Springs, FL.

FounderMr. Thomas H. Jensen

President & Chief Development OfficerDr. Jeremy R. Graff Ph.D.

Founder & Chief Scientific OfficerDr. Steen Meier Knudsen Ph.D.

Chief Financial OfficerMr. Jeffrey S. Ervin M.B.A.

Consultant Chief Medical OfficerDr. Jose L. Iglesias M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLR

Allarity Therapeutics Inc

Upgrade your Finviz experience